Fiona Hegi-Johnson 35th Lorne Cancer Conference 2023

Abstracts this author is presenting:

• Initial biodistribution data of ImmunoPET a Phase 0/1 Study characterising PD-L1 with ⁸⁹Zr- Durvalumab (MEDI4736) PET/CT — Welcome Function & Poster Session I